DE69620639D1 - MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF) - Google Patents

MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF)

Info

Publication number
DE69620639D1
DE69620639D1 DE69620639T DE69620639T DE69620639D1 DE 69620639 D1 DE69620639 D1 DE 69620639D1 DE 69620639 T DE69620639 T DE 69620639T DE 69620639 T DE69620639 T DE 69620639T DE 69620639 D1 DE69620639 D1 DE 69620639D1
Authority
DE
Germany
Prior art keywords
necrosis factor
mmp
tnf
inhibitors
tumor necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620639T
Other languages
German (de)
Other versions
DE69620639T2 (en
Inventor
Andrew Douglas Baxter
John Gary Montana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523828.3A external-priority patent/GB9523828D0/en
Priority claimed from GBGB9607121.2A external-priority patent/GB9607121D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DE69620639D1 publication Critical patent/DE69620639D1/en
Publication of DE69620639T2 publication Critical patent/DE69620639T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Abstract

Peptidyl compounds having an imidazole substituent have therapeutic utility via their inhibitory effect on metalloproteinases and tumour necrosis factor.
DE69620639T 1995-11-22 1996-11-22 MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF) Expired - Fee Related DE69620639T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9523828.3A GB9523828D0 (en) 1995-11-22 1995-11-22 Compounds
GBGB9607121.2A GB9607121D0 (en) 1996-04-04 1996-04-04 Compounds
PCT/GB1996/002892 WO1997019075A1 (en) 1995-11-22 1996-11-22 Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
DE69620639D1 true DE69620639D1 (en) 2002-05-16
DE69620639T2 DE69620639T2 (en) 2002-10-17

Family

ID=26308152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620639T Expired - Fee Related DE69620639T2 (en) 1995-11-22 1996-11-22 MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF)

Country Status (19)

Country Link
US (1) US6048841A (en)
EP (1) EP0874842B1 (en)
JP (1) JP2000500482A (en)
KR (1) KR19990067687A (en)
CN (1) CN1072667C (en)
AT (1) ATE215946T1 (en)
AU (1) AU711907B2 (en)
BR (1) BR9611636A (en)
CA (1) CA2229438C (en)
CZ (1) CZ291337B6 (en)
DE (1) DE69620639T2 (en)
ES (1) ES2172690T3 (en)
HU (1) HUP9904131A3 (en)
IL (1) IL123431A (en)
MX (1) MX9804052A (en)
NO (1) NO982290D0 (en)
NZ (1) NZ322565A (en)
PL (1) PL326710A1 (en)
WO (1) WO1997019075A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
RU2201931C2 (en) 1996-11-20 2003-04-10 Биомежер Инкорпорэйтед Inhibitors of farnesyltransferase and methods of inhibition of farnesyltransferase
KR100840816B1 (en) 2000-05-12 2008-06-23 젠자임 코포레이션 MODULATORS OF TNF-¥áSIGNALING
WO2001087870A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
SE0100903D0 (en) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (en) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (en) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
EP1474425B9 (en) * 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
SE0202539D0 (en) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
WO2004047825A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (en) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0403085D0 (en) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (en) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
PL227790B1 (en) 2015-08-13 2018-01-31 Slaski Univ Medyczny W Katowicach Phosphonates of acetylene derivatives of betulin with antitumour effects, method for producing them and applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
PL183510B1 (en) * 1994-10-05 2002-06-28 Darwin Discovery Ltd Peptide compounds and their therapeutic application as inhibitors

Also Published As

Publication number Publication date
CN1072667C (en) 2001-10-10
IL123431A0 (en) 1998-09-24
EP0874842B1 (en) 2002-04-10
PL326710A1 (en) 1998-10-26
EP0874842A1 (en) 1998-11-04
NZ322565A (en) 1999-11-29
CZ291337B6 (en) 2003-02-12
IL123431A (en) 2001-05-20
AU711907B2 (en) 1999-10-21
CA2229438A1 (en) 1997-05-29
MX9804052A (en) 1998-09-30
ES2172690T3 (en) 2002-10-01
DE69620639T2 (en) 2002-10-17
BR9611636A (en) 1999-12-28
WO1997019075A1 (en) 1997-05-29
AU7634396A (en) 1997-06-11
NO982290L (en) 1998-05-20
CN1202895A (en) 1998-12-23
CZ145598A3 (en) 1998-08-12
US6048841A (en) 2000-04-11
HUP9904131A2 (en) 2000-06-28
ATE215946T1 (en) 2002-04-15
CA2229438C (en) 2006-01-17
KR19990067687A (en) 1999-08-25
HUP9904131A3 (en) 2002-04-29
NO982290D0 (en) 1998-05-20
JP2000500482A (en) 2000-01-18

Similar Documents

Publication Publication Date Title
DE69620639T2 (en) MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF)
DE69631423D1 (en) CHINOLONES AND THEIR THERAPEUTIC USE
NO961888L (en) Peptidyl compounds and their therapeutic use as inhibitors of metal proteinases
ES2133807T3 (en) PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS METALOPROTEASE INHIBITORS.
DE69722656D1 (en) BICYCLIC ARYLCARBOXAMIDS AND THEIR THERAPEUTIC USE
NO990543L (en) Hydroxamic and carboxylic acid derivatives with MMP and TNF inhibitory activity
DE69723863D1 (en) CHINOLINE AND THEIR THERAPEUTIC USE
DE69835518D1 (en) IMIDAZOLYL-CYCLIC ACETALE
NO20005448L (en) Indole derivatives and their use in the treatment of malignant and other diseases based on pathological cell proliferation
BR9805544A (en) Use of a compound.
BG103832A (en) Leptin as tumour cells proliferation inhibitor
ES2000734A6 (en) Hydroxy and alkoxy pyrimidines.
MX9802680A (en) Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation.
ATE415961T1 (en) THERAPEUTIC USE OF MEMBERS OF THE N,N-DICYLCOHEXYL-2-HYDROXY-7,7-DIMETHYLBICYCLOÄ2.2.1ÜHEPT-1-YLMETHANESULPHONAMIDE FAMILY
NO975503L (en) 4,4- (Disubstituted) Cyclohexan-1-oler Monomers and Related Compounds
DE69217221D1 (en) Hydroquinone derivatives and antioxidants containing them, as well as tumor inhibitors
ATE286892T1 (en) HYDROXAM AND CARBOXYLIC ACID DERIVATIVES WITH MMP AND TNF INHIBITING ACTIVITY
ATE275955T1 (en) USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASE CORONARY BLOOD FLOW
FI972676A (en) 4,4- (disubstituted) cyclohexane olonomers and the like
ATE215935T1 (en) HETEROCYCLIC COMPOUNDS WITH MMP AND TNF INHIBITORY ACTION
NZ330616A (en) Potentiation of temozolomide toxicity in human cancer cells using inhibitors of ATase
PA8436101A1 (en) NAALADASA ENZYME ACTIVITY INHIBITORS.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee